SPRINGFIELD, Mo., Sept. 24, 2026 (GLOBE NEWSWIRE) — Great Southern Bancorp, Inc. (NASDAQ:GSBC), the holding company for Great Southern Bank, expects to report third quarter preliminary earnings after the market closes on Wednesday, October 21, 2026, and host a conference call on Thursday, October 22, 2026, at 2:00 p.m. Central Time (3:00 p.m. Eastern Time).

The call will be available live or later in a recorded version at the Company’s Investor Relations website, https://investors.greatsouthernbank.com.

Participants may register for the call here. While not required, it is recommended that participants join 10 minutes prior to the event start. Instructions are provided to ensure the necessary audio applications are downloaded and installed. Users can obtain these programs at no cost.

The Company will notify the public that third quarter 2026 results have been issued through a news release and will post the results to the Company’s Investor Relations website. The earnings release will also be available on the Securities and Exchange Commission’s (SEC) website, www.sec.gov, as an exhibit to a Current Report on Form 8-K that will be furnished by the Company to the SEC.

About Great Southern Bank

Headquartered in Springfield, Missouri, Great Southern offers a broad range of banking services to customers. The Company operates 87 retail banking centers in Missouri, Iowa, Kansas, Minnesota, and Nebraska and commercial lending offices in Atlanta, Charlotte, Chicago, Dallas, Denver, and Phoenix. The common stock of Great Southern Bancorp, Inc. is listed on the Nasdaq Global Select Market under the symbol “GSBC.”

CONTACT:

Kincade Ayers,
Investor Relations,
(616) 233-0500
GSBC@lambert.com

WINTER PARK, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) — CTO Realty Growth (NYSE: CTO) (the “Company”) announced today that it will report its financial and operating results for the third quarter of 2026 after the market closes on Tuesday, October 27, 2026. A conference call to discuss its financial and operating results is scheduled for Wednesday, October 28, 2026 at 9:00 AM ET.

A live webcast of the call will be available on the Investor Relations page of the Company’s website at www.ctoreit.com or at the link provided in the event details below. To access the call by phone, please go to the registration link provided in the event details below and you will be provided with dial-in details.

Event Details:  
Webcast: https://edge.media-server.com/mmc/p/fu529fsr
Registration: https://register-conf.media-server.com/register/BI7d08c73e0701499d94825c3c59fee239
   

We encourage participants to register and dial into the conference call at least fifteen minutes ahead of the scheduled start time. A replay of the earnings call will be archived and available online through the Investor Relations section of the Company’s website at www.ctoreit.com.

About CTO Realty Growth, Inc.

CTO Realty Growth, Inc. owns and operates high-quality, open-air shopping centers located primarily in the higher growth Southeast and Southwest markets of the United States. CTO also externally manages and owns a meaningful interest in Alpine Income Property Trust, Inc. (NYSE: PINE).

We encourage you to review our most recent investor presentation and supplemental financial information, which is available on our website at www.ctoreit.com.

CONTACT: Contact:
Investor Relations
ir@ctoreit.com

WINTER PARK, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) — Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”) announced today that it will report its financial and operating results for the third quarter of 2026 after the market closes on Thursday, October 22, 2026. A conference call to discuss its financial and operating results is scheduled for Friday, October 23, 2026 at 9:00 AM ET.

A live webcast of the call will be available on the Investor Relations page of the Company’s website at www.alpinereit.com or at the link provided in the event details below. To access the call by phone, please go to the link provided in the event details below and you will be provided with dial-in details.

Event Details:  
Webcast: https://edge.media-server.com/mmc/p/gx2epmx6
Registration:  https://register-conf.media-server.com/register/BIdda2983b5d4a42ac87f47a22c6553594
   

We encourage participants to register and dial into the conference call at least fifteen minutes ahead of the scheduled start time. A replay of the earnings call will be archived and available online through the Investor Relations section of the Company’s website at www.alpinereit.com.

About Alpine Income Property Trust, Inc.

Alpine Income Property Trust, Inc. (NYSE: PINE) is a publicly traded real estate investment trust that seeks to deliver attractive risk-adjusted returns and dependable cash dividends by investing in, owning and operating a portfolio of single tenant net leased commercial income properties that are predominately leased to high-quality publicly traded and credit-rated tenants. The Company also complements its income property portfolio by strategically investing in a select portfolio of commercial loan investments intended to deliver an attractive risk-adjusted return.

We encourage you to review our most recent investor presentation which is available on our website at http://www.alpinereit.com.

CONTACT: Contact:
Investor Relations
ir@alpinereit.com

RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Stifel 2026 Virtual Cardiometabolic Forum taking place on September 30, 2026.

Stifel 2026 Virtual Cardiometabolic Forum
Date:   Wednesday, September 30, 2026
Time:    12:00pm ET
Format:    Fireside Chat

A live webcast of this fireside chat can be accessed on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.

About Mineralys Therapeutics
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Contact:

Investor Relations investorrelations@mineralystx.com

GEORGE TOWN, Cayman Islands, Sept. 24, 2026 (GLOBE NEWSWIRE) — Bullish (NYSE:BLSH) and Equiniti today announced the formation of the Issuer Sponsored Token Coalition, a multi-stakeholder industry working group bringing together leading firms across brokerage, trading and market infrastructure to advance issuer-sponsored tokenized securities.

Alpaca, Apex Fintech Solutions and DriveWealth are among the first market infrastructure participants joining Bullish and Equiniti in the Coalition, which is being established to help develop the technical standards, market infrastructure and operating frameworks necessary for tokenized securities to scale alongside, and interoperate with, the existing capital markets ecosystem.

The Coalition is founded on the belief that the next generation of tokenized public securities should preserve the fundamental relationship between an issuer and its shareholders. Under an issuer-sponsored model, tokenized securities can be directly connected to the issuer’s authoritative shareholder register, helping preserve ownership rights, corporate-action entitlements and investor protections while enabling the benefits of blockchain-based market infrastructure.

The launch follows the U.S. Securities and Exchange Commission’s Sept. 17 Innovation Exemption, which permits limited onchain trading of U.S.-listed equities. The order requires venues to verify that a tokenized stock gives holders the same rights and privileges as the equivalent traditional share, which highlights the leadership role that ISTs are positioned to have as the new market evolves. The relief runs for five years, and the Commission is seeking public comment on how the framework should evolve.

“Tokenization will turn static, opaque assets into active, transparent digital shares. The architecture we establish now matters and that is why we are bringing together this group of leading firms to chart the course,” said Tom Farley, CEO of Bullish. “Public companies should remain at the center of the relationship with their shareholders as we combine the advantages of blockchain technology with the protections and market structure that make public markets work.”

The Coalition will focus initially on four areas:

  • Preserving issuer and shareholder rights: advancing a regulated model for tokenized securities that maintains the legal rights, corporate-action entitlements and investor protections associated with traditionally held shares.
  • Building interoperability: developing common technical and operational approaches that allow issuer-sponsored securities to move across traditional clearing and settlement infrastructure, blockchain networks, wrapped-token models and emerging entitlement-token frameworks.
  • Creating the infrastructure for adoption: addressing the regulatory, operational and commercial requirements surrounding issuance, transfer, settlement, custody and secondary-market trading.
  • Growing an open market ecosystem: bringing together issuers, broker-dealers, exchanges, transfer agents, custodians, market makers, liquidity providers and technology companies to support a scalable tokenized securities market.

The Coalition expects its work to include evaluation of blockchain and smart-contract architectures, development of interoperability standards, analysis of regulatory and compliance requirements, product prototyping and pilots, and engagement with policymakers, industry bodies and standards organizations. The group is intended to be open and non-exclusive, with additional market participants who share the vision invited to join over time.

“Tokenization creates an opportunity to connect issuers and investors in ways that weren’t possible with traditional market infrastructure,” said Arush Sehgal, Head of Digital Assets at Alpaca. “Getting it right means preserving shareholder rights and ensuring onchain markets remain connected to the markets they’re built on. We’re joining the Coalition to help advance the interoperability between traditional and onchain markets that allows tokenized equities and their traditional counterparts to be converted through Alpaca’s Instant Tokenization Network.”

“Tokenized securities will only scale if they preserve the relationships and protections that market participants rely on today,” said Travis McGhee, Global Head of Digital Markets at Apex Fintech Solutions. “Apex operates across issuers, broker-dealers and investors, so we see firsthand how important connective infrastructure is. We’re joining the Coalition to help advance standards that allow tokenized markets to scale responsibly.”

“Much of what’s marketed today as ‘tokenized equity’ isn’t equity at all. Investors think they own the share, and they don’t. That’s the gap this Coalition is built to close,” said Naureen Hassan, CEO of DriveWealth. “An issuer-sponsored model preserves real ownership with the same shareholder rights, voting and corporate-action entitlements investors have today, even as the rails move on-chain. Innovation and genuine ownership have never been competing goals. They’re both what make a market worth investing in, and we’re glad to help build it that way from the start.”

Bullish and Equiniti are developing infrastructure designed to support issuer-sponsored tokenized securities while maintaining an authoritative shareholder register and enabling interoperability with traditional capital-market infrastructure and blockchain-based markets. The Coalition expands that effort by bringing together participants responsible for many of the critical functions between issuers and investors.

Coalition members will convene with issuers and other capital-market leaders at the New York Stock Exchange on October 27 for a discussion focused on how public companies can approach tokenization, what infrastructure is required to support it, and how issuer-sponsored models can connect traditional securities markets with emerging blockchain-based rails.

Additional Coalition participants and initiatives will be announced in the coming weeks.

About the Issuer Sponsored Token Coalition

The Issuer Sponsored Token Coalition is a non-exclusive industry working group convened by Bullish and Equiniti to explore and advance the infrastructure, standards and commercial ecosystem required to support issuer-sponsored tokenized securities. Participants include firms across brokerage, exchanges, transfer agency, custody, liquidity, technology and other areas of market infrastructure. Participation in the Coalition is non-binding and does not require any participant to enter into a commercial arrangement, issue or list a security, provide liquidity or support any particular product.

Media Contact: media@bullish.com

About Bullish
Bullish (NYSE: BLSH) is an institutionally focused global digital asset platform that provides regulated market infrastructure and information services. This includes Bullish Exchange — an institutionally focused digital assets spot and derivatives exchange, integrating a high-performance central limit order book matching engine with automated market making to provide deep and predictable liquidity. Bullish Europe is regulated under MiCAR as a crypto asset service provider offering spot trading and custody services for digital assets.

Bullish is the parent company of CoinDesk, a leading provider of digital asset media and information services. CoinDesk’s offerings include: CoinDesk Indices — a collection of tradable proprietary and single-asset benchmarks and indices that track the performance of digital assets for global institutions in the digital assets and traditional finance industries; CoinDesk Data — a broad suite of digital asset market data and analytics, providing real-time insights into prices, trends and market dynamics; and CoinDesk Insights — a digital asset media and events provider and operator of coindesk.com, a digital media platform that covers news and insights about digital assets, the underlying markets, policy and blockchain technology.

In May 2026, Bullish agreed to acquire Equiniti in a $4.2 billion transaction to create the world’s leading transfer agent for tokenized securities. The combined platform is designed to span the full lifecycle of a tokenized security, from issuance and registry through to trading. The transaction is expected to close in January 2027, subject to customary closing conditions and required regulatory approvals.

For more information, please visit bullish.com and follow LinkedIn and X.

Use of Websites to Distribute Material Company Information
We use the Bullish Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the U.S. Securities and Exchange Commission (SEC) and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Sentences containing words such as “believe,” “intend,” “plan,” “may,” “will,” “expect,” “should,” “could,” “anticipate,” “estimate,” “predict,” “project,” or their negatives, or other similar expressions of a future or forward-looking nature generally should be considered forward-looking statements and include, without limitation, statements relating to the acquisition of Equiniti, the timing of, and our ability to obtain, maintain, and operate under, regulatory approvals, authorizations, licenses, registrations, and consents, future events or Bullish’s future financial or operating performance, business strategy, and potential market opportunity of Bullish, Equiniti or the combined companies, our plans and expectations related to tokenization and the growth and adoption of tokenized securities and blockchain technology, competition in our industry, the regulatory and legal environment, including regulatory proceedings or approvals, and general economic and business conditions. Such forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Bullish, are inherently uncertain and are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause results to differ from those expressed in our forward-looking statements include, but are not limited to, the satisfaction of the conditions to closing the acquisition of Equiniti in the anticipated timeframe or at all, the failure to obtain necessary regulatory approvals, the ability to realize the anticipated benefits of the combination, the ability to successfully integrate the business, litigation or regulatory actions related to the acquisition and combination, disruption from the acquisition and combination and its impact on our ability to grow our business and operations, including in new geographic locations, the costs or expenditures associated therewith, competition in our industry, and the evolving rules and regulations applicable to digital assets, tokenization and our industry. You should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made, and Bullish undertakes no duty to update these forward-looking statements.

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) — At the end of the settlement date of September 15, 2026, short interest in 3,862 Nasdaq Global MarketSM securities totaled 18,116,572,644 shares compared with 18,212,067,019 shares in 3,860 Global Market issues reported for the prior settlement date of August 31, 2026. The mid-September short interest represents 3.55 days compared with 3.52 days for the prior reporting period.

Short interest in 1,654 securities on The Nasdaq Capital MarketSM totaled 4,404,738,050 shares at the end of the settlement date of September 15, 2026, compared with 4,373,853,400 shares in 1,655 securities for the previous reporting period. This represents a 1.76 day average daily volume; the previous reporting period’s figure was 1.61.

In summary, short interest in all 5,516 Nasdaq® securities totaled 22,521,310,694 shares at the September 15, 2026 settlement date, compared with 5,515 issues and 22,585,920,419 shares at the end of the previous reporting period. This is 2.96 days average daily volume, compared with an average of 2.86 days for the prior reporting period.

The open short interest positions reported for each Nasdaq security reflect the total number of shares sold short by all broker/dealers regardless of their exchange affiliations. A short sale is generally understood to mean the sale of a security that the seller does not own or any sale that is consummated by the delivery of a security borrowed by or for the account of the seller.

For more information on Nasdaq Short interest positions, including publication dates, visit
https://www.nasdaq.com/market-activity/quotes/short-interest
or http://www.nasdaqtrader.com/asp/short_interest.asp.

About Nasdaq:
Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.     

NDAQO

Nasdaq

Media Contact:
Sam Raffalli
sam.raffalli@nasdaq.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4272a2c4-7b47-4f7f-89b4-aed82307a8a7

REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026.

Tumor HI

  • upLIFT, a Phase 3, single-arm, open label study in up to 16 hospitalized participants for the treatment of tumor HI, is ongoing.
    • Enrollment is in progress and topline results are expected before the end of 2026.
  • In June 2026, the Company shared positive interim data from the upLIFT study, announcing that of the 8 participants enrolled, 6 had already met the responder criterion for the study’s primary endpoint within the 8-week pivotal treatment phase. Each of these 6 participants also achieved a complete discontinuation of intravenous glucose requirements with the administration of ersodetug. Since the time of this announcement, the seventh participant has also met the responder criterion for the study’s primary endpoint.
    • One of the 8 enrolled participants withdrew study consent and discontinued ersodetug and all other non-palliative therapies prior to completion of the pivotal treatment phase. This patient had Stage 4 metastatic colon cancer and a poor Eastern Cooperative Oncology Group performance status (ECOG 4). The participant elected to be discharged from the hospital to receive hospice care at home, where they died one week later due to cancer progression. The reduction and eventual discontinuation of intravenous glucose were undertaken in the setting of hospice transition, so the participant is being counted as a non-responder for purposes of assessing the primary endpoint.
  • In June 2026 at the Annual Meeting of the Endocrine Society (ENDO), Rezolute delivered a poster presentation highlighting favorable outcomes from a case series report of 9 patients with refractory hypoglycemia due to malignant insulinoma and non-islet cell tumors (tumor HI), demonstrating that 75% of the patients receiving IV dextrose/total parenteral nutrition (TPN) in the EAP achieved a complete discontinuation of IV dextrose/TPN.
    • The outcomes of this case series were also recently published in manuscript form in The Journal of Clinical Endocrinology & Metabolism (JCEM), titled Ersodetug for refractory hypoglycemia due to malignant insulin-secreting tumors.

Congenital HI

  • In September 2026, the Company provided an update that data from the Phase 3 sunRIZE study in congenital HI, which did not meet its primary endpoint, remains under review with the U.S. Food and Drug Administration (FDA or Agency).
    • In June 2026, the Company provided additional study data for the Agency’s independent review, including source and analysis datasets and summary results from a substantial number of pre-specified, post-hoc, and sensitivity analyses with a focus on continuous glucose monitoring (CGM) based glucose outcomes from the pivotal portion of the study.
    • The open-label extension (OLE) phase of the sunRIZE study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in the use of background standard of care therapies.
    • Rezolute will continue to await feedback and reserves the ability to request a formal meeting under a regulatory timeline, as needed.
  • In June 2026 at ENDO, Rezolute delivered three data presentations focused on congenital HI.
    • In an oral presentation, Huseyin Demirbilek, M.D., Professor, Department of Pediatric Endocrinology, Hacettepe University Faculty of Medicine, Ankara, Turkey, and Principal Investigator of the Phase 3 sunRIZE study, reviewed previously reported results from the study.
    • Two poster presentations highlighted results from systematic analyses of natural history and adverse neurologic and health-economic outcomes resulting from congenital HI, using a meta-analysis of the literature as well as a claims-based approach to quantifying congenital HI complications, respectively.

Fourth Quarter and Full Year Fiscal 2026 Financial Results

Cash, cash equivalents and investments in marketable securities were $107.8 million as of June 30, 2026, compared with $167.9 million as of June 30, 2025.

Research and development (R&D) expenses were $14.9 million for the fourth quarter of fiscal 2026, compared with $20.9 million for the same period a year ago. Full fiscal year 2026 R&D expenses were $53.8 million, compared to $61.5 million in fiscal year 2025. The decrease from fiscal year 2025 to fiscal year 2026 was primarily due to decreased manufacturing costs for ersodetug, partially offset by increased employee-related stock-based compensation expense. R&D expenses include $6.5 million of share-based compensation expense for the fiscal year 2026, compared with $3.5 million for fiscal year 2025.

General and administrative (G&A) expenses were $6.7 million for the fourth quarter of fiscal 2026, compared with $5.0 million for the same period a year ago. Full fiscal year 2026 G&A expenses were $29.2 million, compared to $18.4 million in fiscal year 2025. The increase was primarily attributable to increased employee-related stock-based compensation expense, and an increase in professional fees in preparation for future ersodetug commercial activities. G&A expenses include $8.0 million of share-based compensation expense for fiscal 2026, compared with $3.6 million for fiscal year 2025.

Net loss was $20.5 million for the fourth quarter of fiscal 2026 compared with a net loss of $24.4 million for the same period a year ago. Full year fiscal 2026 net loss was $77.6 million compared to net loss of $74.4 million for the fiscal year 2025.

About Ersodetug

Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of hyperinsulinism (HI), including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia. Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority. 

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com. 

Forward-Looking Statements

This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. These forward-looking statements include, but are not limited to, the potential efficacy of ersodetug in treating hypoglycemia as well as our ability to complete enrollment of the upLIFT study this year and announce topline results. Our ability to predict results or our plans or strategies is inherently uncertain. Notably, no assurance can be given that FDA will agree with the Company that there is evidence of clinically meaningful benefit observed in the sunRIZE study and accordingly the Agency could make the determination that the only path forward for the congenital HI indication is a new randomized control trial similar to sunRIZE. Should the Agency make such a determination, that would adversely impact the Company’s ability to further pursue that indication as well as the commercial potential for ersodetug. Actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. 

Rezolute Contacts:

Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
cmckim@rezolutebio.com
336-608-9706

Rezolute, Inc.
Condensed Consolidated Financial Statements Data
(in thousands, except per share data)
               
  Three Months Ended   Year Ended
  June 30,   June 30,
    2026       2025       2026       2025  
Condensed Consolidated Statements of Operations Data:              
               
Operating expenses:              
Research and development $ 14,889     $ 20,863     $ 53,798     $ 61,527  
General and administrative   6,673       4,987       29,168       18,367  
Total operating expenses   21,562       25,850       82,966       79,894  
Loss from operations   (21,562 )     (25,850 )     (82,966 )     (79,894 )
Non-operating income, net   1,071       1,460       5,380       5,482  
Net loss $ (20,491 )   $ (24,390 )   $ (77,586 )   $ (74,412 )
               
Basic and diluted net loss per common share $ (0.20 )   $ (0.26 )   $ (0.75 )   $ (0.98 )
               
Shares used to compute basic and diluted net loss per common share   104,488       94,340       103,907       75,999  
               
  June 30,   June 30,        
    2026       2025          
               
Condensed Consolidated Balance Sheets Data:              
Cash and cash equivalents $ 10,615     $ 94,107          
Investments in marketable debt securities   97,186       73,751          
Working capital   99,093       159,233          
Total assets   112,849       175,490          
Accumulated deficit   (481,442 )     (403,856 )        
Total stockholders’ equity   100,687       162,127          

Veteran leader and Head of Worldwide Sales promoted to lead global revenue operations and expand Zscaler platform adoption

SAN JOSE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — Zscaler, Inc. (NASDAQ: ZS), the cybersecurity platform for the AI era, today announced the appointment of Ross Tackett as the company’s Chief Revenue Officer, effective October 1, 2026. In this role, Tackett will lead Zscaler’s global revenue operations, sales organization, strategic partner ecosystem, and go-to-market execution.

Tackett, who most recently served as Zscaler’s Head of Worldwide Sales, has been with the company for three years and brings more than three decades of technology sales leadership experience and a proven track record of scaling multi-billion-dollar enterprise go-to-market organizations, accelerating international expansion, and building high-performing revenue teams. He previously spent more than a decade in sales leadership roles at ServiceNow, and more than 16 years in sales leadership roles at Dell. Tackett succeeds Mike Rich who is stepping down as CRO for personal reasons. Rich will remain with Zscaler as a strategic advisor through December 31, 2026.

“Ross Tackett brings an exceptional combination of operational discipline, global scale, and customer-first leadership to this important role,” said Jay Chaudhry, CEO, Chairman, and Founder of Zscaler. “Having worked closely with Ross as Head of Worldwide Sales, I have seen firsthand his ability to inspire teams, execute at scale, and drive commercial expansion. His deep domain expertise and international experience throughout his career makes him the ideal leader to guide our global sales organization as enterprises urgently modernize their infrastructure with the Zero Trust Exchange and defend against AI-driven threats. I also want to express my gratitude to Mike Rich for his contributions and leadership, and for staying on to ensure a seamless transition.”

“Zscaler pioneered Zero Trust security and continues to set the benchmark for innovation in the AI era,” said Tackett. “Enterprises worldwide are retiring complex, vulnerable legacy firewall and VPN-based security in favor of Zero Trust architecture, and Zscaler is uniquely positioned as the platform of choice. I look forward to continuing to work closely with Jay, our executive leadership, and our world-class sales organization to scale our global commercial engine and deliver tangible, transformative business outcomes for our customers.”

“Leading Zscaler’s sales organization has been an incredible privilege and I am proud of the milestones our global team has achieved together,” said Rich. “Having partnered side-by-side with Ross, I know our go-to-market team is in outstanding hands. His promotion reflects the strength of our leadership bench, and I look forward to actively supporting him and the company through the end of the year to ensure sustained momentum.”

About Zscaler

Zscaler (NASDAQ: ZS) accelerates digital transformation so customers can be more agile, efficient, resilient, and secure. The Zscaler Zero Trust Exchange™ platform protects thousands of customers from cyberattacks and data loss by securely connecting users, devices, and applications in any location. Distributed across 200+ public data centers globally and thousands of private sites at the edge, the SASE-based Zero Trust Exchange is the world’s largest in-line cloud security platform.

Forward-Looking Statements

This press release contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. These forward-looking statements include, but not limited to, statements regarding our leadership transition, plans, beliefs, and expectations, operational continuity, market opportunities, and strategic growth trajectories. These forward-looking statements are subject to the safe harbor provisions created by the Private Securities Litigation Reform Act of 1995.

There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including but not limited to, our ability to successfully manage the transition, our ability to maintain key relationships with existing customers and prospects, our ability to retain our existing and hire new go-to-market personnel, and our ability to continue to capitalize on our account centric sales motion. Additional risks and uncertainties are included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” set forth from time to time in our filings and reports with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the fiscal year ended July 31, 2026, filed on September 3, 2026, as well as future filings and reports by us, copies of which are available on our website at ir.zscaler.com and on the SEC’s website at www.sec.gov. Any forward-looking statements in this release are based on the limited information currently available to Zscaler as of the date hereof, which is subject to change, and Zscaler will not necessarily update the information, even if new information becomes available in the future.

Media Contacts

Nick Gonzalez, Director of Public Relations, press@zscaler.com

Investor Relations Contacts

Kim Watkins, SVP, Investor Relations & Strategic Finance, ir@zscaler.com


Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 24, 2026 (GLOBE NEWSWIRE) — Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the appointment of Keli Walbert to its Board of Directors, effective September 24, 2026. Ms. Walbert will join the Board’s Audit Committee, succeeding Akshay Vaishnaw, MD, PhD, who will remain a member of the Board.

“Keli’s experience turning novel scientific innovations into therapies that reach patients is exactly what Hemab needs as we work to close longstanding gaps in the treatment of bleeding disorders,” said Benny Sørensen, MD, PhD, CEO of Hemab. “As we advance our pipeline toward later-stage development, her experience building the commercial capabilities that bring new therapies to people with high-unmet-need conditions will strengthen our Board at a pivotal time for Hemab.”

“We are pleased to welcome Keli to Hemab’s Board of Directors. Her commercial expertise strengthens our Board as we work to bring new therapies to people living with serious, underserved bleeding disorders,” said John Maraganore, PhD, Chair of Hemab’s Board of Directors. “Her success launching medicines from very common to rare diseases is a good strategic match as we advance toward key milestones across the pipeline.”

Ms. Walbert brings more than 20 years of commercial leadership experience in biopharmaceuticals, spanning sales and marketing, market access, patient services, advocacy, and analytics. Her therapeutic background covers immunology, rheumatology, dermatology, gastroenterology, ophthalmology, nephrology, neurology and metabolic disease, with experience in indications of all market sizes. She most recently served as Executive Vice President, U.S. Commercial at Horizon Therapeutics, where she oversaw commercial strategy and organizational development across more than 10 marketed brands. Earlier in her career, she held leadership roles at AbbVie, the American Medical Association, Abbott and United Healthcare. Over the course of her career, she led the commercial launches of HUMIRA®, TEPEZZA® and DUOPA®. She has been recognized with the Healthcare Businesswomen’s Association’s Luminary Award and an MM+M Women of Distinction Award. She earned her master’s degree from Northwestern University and bachelor’s degree from the University of Louisville.

“I’m honored to join Hemab’s Board at such a pivotal moment for the company,” said Ms. Walbert. “Hemab’s mission to bring new options to people living with serious, high-unmet-need bleeding disorders reflects the kind of impact I’ve built my career around, and I look forward to helping them move their pipeline to patients as quickly and effectively as possible.”

About Hemab Therapeutics
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an antifibrinolytic targeting plasmin inhibition in clinical development for heavy menstrual bleeding.

Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Hemab’s strategy, future operations, prospects and plans, objectives of management, and the clinical potential of sutacimig, HMB-002 and HMB-003, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Hemab may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Hemab’s ability to initiate and enroll patients in clinical trials; whether results from preclinical studies and earlier clinical trials will be predictive of the results of later clinical trials; whether Hemab’s cash resources will be sufficient to fund Hemab’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Hemab’s filings with the Securities and Exchange Commission (SEC), including Hemab’s most recent Form 10-Q and in subsequent filings Hemab may make with the SEC. In addition, the forward-looking statements included in this press release represent Hemab’s views as of the date of this press release. Hemab anticipates that subsequent events and developments will cause its views to change. However, while Hemab may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Hemab’s views as of any date subsequent to the date of this press release.

Media:
Deerfield Group
Peg Rusconi
peg.rusconi@deerfieldgroup.com

Investors:
Hemab Therapeutics
Mads Behrndt
investors@hemab.com

  • Anthropic to leverage Akamai Cloud’s distributed infrastructure and software to support CPU workload growth at scale
  • The transaction provides for the potential expansion of the relationship by up to an additional $9 billion, which represents a total potential commitment of approximately $20 billion
  • Akamai has issued a warrant to Anthropic, the continued vesting of which is tied to the successful expansion of the relationship, for up to approximately 5% of Akamai’s common stock outstanding. A portion of the warrant representing approximately 2% of Akamai’s common stock outstanding is expected to vest in connection with today’s announced commitment

CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) — Akamai Technologies, Inc. (NASDAQ: AKAM), today announced a significantly expanded relationship with Anthropic for $11.6 billion of contractual commitment over seven years. The multi-year commitment will support Anthropic’s accelerating CPU workload demands by leveraging Akamai Cloud’s distributed AI infrastructure and software.

The deal adds to the more than $2.8 billion in multi-year Cloud Infrastructure Services (CIS) commitments across Akamai’s customer base previously announced this year. These agreements underscore a growing demand for Akamai to enable customers to build, deploy and operate AI workloads at scale.

As part of the increased strategic alignment between Akamai and Anthropic, Akamai has issued a warrant to Anthropic for the purchase of non-voting convertible Series B Preferred Stock representing 7.7 million shares of Akamai’s common stock on an as-converted basis, or up to approximately 5% of Akamai’s common stock outstanding, at an exercise price of $111.33 per share of common stock. A portion of the warrant representing approximately 2% of Akamai’s common stock outstanding is expected to vest in connection with today’s announced $11.6 billion commitment. The remaining approximately 3% would vest throughout the successful expansion of the commitment up to an additional $9 billion within the seven-year term of the warrant. Each additional $3 billion purchase of cloud services, at mutually agreed upon terms, will result in the vesting of approximately 1% of Akamai’s common stock outstanding.

“Anthropic is advancing the AI revolution and we are thrilled they chose Akamai’s capabilities for building and operating AI infrastructure at scale,” said Dr. Tom Leighton, co-founder and CEO, Akamai. “Akamai has an unparalleled reputation for helping our customers achieve their business-critical goals and build the future. Our expanding global footprint, combined with our years of experience serving the world’s largest enterprises, positions us to be the infrastructure provider for secure and responsible AI applications and workloads.”

Akamai Cloud supports a continuum of compute from core to edge, with a vastly distributed network spanning thousands of points of presence. The platform is built with diversified hardware to enable customers to build and run applications and optimize how they are served to their users and agents. Akamai’s global infrastructure enables the full lifecycle of applications in the AI era, and ensures they are fast, reliable and secure.

Total capital expenditures related to today’s $11.6 billion commitment are estimated to be approximately $5.5 billion. Akamai anticipates no impact to the company’s 2026 revenue guidance, and an increase of approximately $1.7 billion in capital expenditures in 2026 to secure and pre-purchase critical supply chain components, including memory.

The company will host a conference call today at 5:30 p.m. Eastern Time. The call can be accessed via 1-833-634-5020 (or 1-412-902-4238 for international calls) and using passcode Akamai Technologies Call. A live webcast of the call may be accessed at www.akamai.com in the Investor Relations section. In addition, a replay of the call will be available for two weeks following the conference by calling 1-855-669-9658 (or 1-412-317-0088 for international calls) and using passcode 2566572. The archived webcast of this event may be accessed through the Akamai website.

About Akamai
Akamai is the cloud company that powers and protects an AI-driven world. Our cloud platform extends high-performance cloud computing from the core to the edge, enabling organizations to build and scale next-generation AI applications while delivering comprehensive, multi-layered security to safeguard enterprises against evolving cyber threats. Learn more at akamai.com and akamai.com/blog, or follow Akamai Technologies on X and LinkedIn.

Akamai Statement Under the Private Securities Litigation Reform Act
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding future events and the future results of Akamai. All statements other than statements of historical facts are statements that could be deemed forward-looking statements. Such forward-looking statements include, but are not limited to, statements about Akamai’s capabilities, the expected benefits of the transaction to Akamai, the potential impact of the issuance of the warrant, the potential expansion of the relationship between Akamai and Anthropic and the impact of the transaction on Akamai’s financial condition and financial guidance. These statements are subject to risks and uncertainties and are based on the beliefs and assumptions of Akamai’s management as of the date hereof based on information currently available to Akamai’s management. Use of words such as “believes,” “could,” “expects,” “anticipates,” “intends,” “plans,” “seeks,” “projects,” “estimates,” “should,” “would,” “forecasts,” “if,” “continues,” “goal,” “likely,” “may,” “will,” variations of such words or similar expressions are intended to identify a forward-looking statement. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions. Actual results may differ materially from the forward-looking statements Akamai makes as a result of various factors, including, but not limited to: Akamai being unable to achieve the anticipated benefits of the transaction; Akamai’s capabilities failing to meet expectations, including due to defects, security breaches, delays in performance or other similar problems; effects of competition, including pricing pressure, data center capacity and changing business models; impact of macroeconomic trends, including economic uncertainty, turmoil in the financial services industry, the effects of inflation, rising and fluctuating interest rates, foreign currency exchange rate fluctuations, securities market volatility and monetary supply fluctuations; potential cash flow constraints and the ability to raise capital; continuing supply chain and logistics costs, constraints, changes or disruptions; defects or disruptions in Akamai’s products or IT systems, including cyber-attacks, data breaches or malware; changes to economic, political and regulatory conditions in the United States or internationally; and other factors that are discussed in the company’s most recent Annual Report on Form 10-K, subsequent quarterly reports on Form 10-Q and other documents filed with the Securities and Exchange Commission. Potential investors, stockholders and other readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. Akamai disclaims any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

Contacts:
Johanna Schmitt   Mark Stoutenberg
Media Relations   Investor Relations
Akamai Technologies   Akamai Technologies
AkamaiPR@akamai.com   mstouten@akamai.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.